What is Celularity?
Celularity Inc. is a prominent player in the regenerative and cellular medicines landscape, dedicated to developing innovative therapies for aging-related and degenerative conditions. The company's core focus lies in the creation of off-the-shelf placental-derived allogeneic cell therapy product candidates. These include advanced treatments such as mesenchymal-like adherent stromal cells, targeting debilitating conditions like diabetic foot ulcers and Crohn's disease. Celularity operates across three key segments: Cell Therapy, Degenerative Disease, and BioBanking, demonstrating a comprehensive approach to cellular medicine. Its therapeutic pipeline features promising candidates like PDA-001 for autoimmune and degenerative diseases, and PDA-002 aimed at treating facioscapulohumeral muscular dystrophy, highlighting a commitment to pioneering new treatment modalities.
How much funding has Celularity raised?
Celularity has raised a total of $285.1M across 6 funding rounds:
Unspecified
$250M
Multiple Rounds
$21.8M
Other Financing Round
$13.3M
Unspecified (2018): $250M with participation from United Therapeutics, Sorrento Therapeutics, Heritage Group, Celgene, Human Longevity, Genting Berhad, the Dreyfus Family Office, and Section 32
Private Equity (2025): $1M, investors not publicly disclosed
Private Equity (2025): $2M, investors not publicly disclosed
Debt (2025): $6.8M, investors not publicly disclosed
Debt (2025): $12M, investors not publicly disclosed
Other Financing Round (2026): $13.3M with participation from NEXGEL
Key Investors in Celularity
NEXGEL
NEXGEL is a healthcare and materials science company focused on advanced hydrogel-based patches and transdermal delivery systems for wound care and cosmetics. Their expertise lies in electron-beam cross-linked hydrogel technology for gentle active ingredient delivery.
United Therapeutics
Unither Pharmaceuticals is a global contract development and manufacturing organization (CDMO) specializing in single-dose liquid pharmaceuticals and sterile unit-dose formats, recognized for its leadership in blow-fill-seal technology.
Sorrento Therapeutics
Sorrento Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer, leveraging its expertise in antibody-centric drug development.
What's next for Celularity?
The recent strategic investment in Celularity signals a pivotal moment for the company's growth trajectory. This capital infusion is expected to accelerate the development and commercialization of its innovative cell therapy product candidates. With a clear focus on addressing unmet medical needs in degenerative diseases and aging, Celularity is poised to expand its clinical trials, enhance its manufacturing capabilities, and potentially broaden its market reach. The company's enterprise-level funding context suggests a strategic phase focused on scaling operations and solidifying its position as a leader in the regenerative medicine field.
See full Celularity company page
